Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up
BioCentury This Week
00:00
The First Check Point Inhibitor Against a New Target
This is the first new check point inhibitor against a new target since the first p d one p d approvals, which were about eight years ago now. And it's a big moment for the field. You know, i think we should acknowledge that bemess has been, in some ways, out in front rate. So they've really been out in front of the ncology space, and it will be interesting to see what they come up with next.
Transcript
Play full episode
